Live Online Training: Pre-Conference Session APIC/CEFIC Conference: Nitrosamine Impurities - GMP and Regulatory requirements
Tuesday, 27 October 2020 9 .30 - 18.00 h
Course No. 17692
Speakers
Marieke van Dalen
MARA Consultancy, The Netherlands
Dr. Ulrich Kissel
European QP Association (EQPA), KisselPharmaConsulting
Objectives
During this pre-Conference Session you will hear an update on how to deal with Nitrosamine Impurities from a GMP perspective and how to handle cases of Nitrosamine contamination in terms of filing changes/variations. You will get to know
Which “lessons learned” future risk mitigation strategies can be based on
How a comprehensive supply chain quality oversight should look like
What has to be considered regarding the CEP procedure in case of Nitrosamine Impurities
You will receive first hand information from speakers representing the European QP Association and APIC.
This pre-conference session ideally complements the following 23rd APIC/CEFIC Global GMP & Regulatory API Conference.
Background
In June 2018 EU authorities were notified that a Chinese API manufacturer has detected the presence of N-nitrosodimethylamine, NDMA, in batches of Valsartan. NDMA is known to be genotoxic and carcinogenic and is classified as a Class 2A carcinogen to humans. After a referral under Article 31 of Directive 2001/83/EC the CHMP assessed the impact of the presence of this impurity on the benefit-risk balance of valsartan-containing drug products and issued a recommendation whether the concerning marketing authorisations can still be maintained or should be suspended.
Meanwhile, different Nitrosamines (NDMA, NDEA and others) were detected in almost every drug product which contains a sartan derivative as an API. Marketing Authorisation Holders have been requested to evaluate the risk of the presence of Nitrosamine impurities in human medicinal products containing chemically synthesised APIs.
Target Group
This pre-conference session is of interest to all personnel involved in risk assessments of drug substances and drug products regarding potential Nitrosamine contamination. Scientific staff, Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments as well as people working in the regulatory affairs area are addressed.
To find alternative dates for this training/webinar or similar events please see the complete list of all events.
For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.
Testimonials
Seminar Programme as PDF